EUVIMEDSkopri EUVIMED
ValidierungsstudieOpen access · CC BY 4.0

Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry

Mégane Moreau, Serge Auger, Pierre Picard, Jean Lacoursière, Pedro A Segura iD

Rapid Communications in Mass Spectrometry · 2024

DOI: 10.1002/rcm.9855 ↗

At a glance

Validierungsstudie in Rapid Communications in Mass Spectrometry, 2024. Written by Mégane Moreau and 4 co-authors. Institution: Department of Chemistry, Université de Sherbrooke, Sherbrooke, QC, Canada. Major MEDLINE topics: Rivaroxaban, Tandem Mass Spectrometry. Cited 1 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Rationale

Rivaroxaban is an anticoagulant prescribed to patients who are at risk of medical conditions such as deep‐vein thrombosis, pulmonary embolisms, and strokes caused by blood clots. The administration of this drug is monitored to adjust the dosage and evaluate patients' blood concentration. Rapid quantification of this drug in plasma could make it possible to ensure that the dose present in the blood of patients does not represent a danger for the medical intervention to be carried out.

Methods

Liquid chromatography–tandem mass spectrometry is usually employed to quantify rivaroxaban in blood, plasma, and serum. Here, an alternative method of analysis based on laser diode thermal desorption–triple quadrupole mass spectrometry (LDTD‐QqQMS) was developed and comprehensively validated. This new method allows the quantification of rivaroxaban in less than 13 s from sample to sample. The extraction of rivaroxaban in human serum was done by a salting‐out liquid–liquid extraction with acetonitrile and a saturated sodium chloride solution.

Results

The proposed method allows the quantification of rivaroxaban in less than 13 s from sample to sample. During validation, all criteria were respected. The accuracy was

Subjects

MeSH terms (MEDLINE)

RivaroxabanTandem Mass SpectrometryHumansReproducibility of ResultsLimit of DetectionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationLinear Models

Substances

Rivaroxaban

Authors and institutions

  • Department of Chemistry, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Phytronix Technologies, Québec, Canada.

ORCID profiles: Pedro A Segura

Cite

APA

Moreau, M., Auger, S., Picard, P., Lacoursière, J., & Segura, P. A. (2024). Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9855

Vancouver

Moreau M, Auger S, Picard P, Lacoursière J, Segura PA. Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry. 2024. doi:10.1002/rcm.9855

BibTeX
@article{Moreau2024,
  author = {Moreau, Mégane and Auger, Serge and Picard, Pierre and Lacoursière, Jean and Segura, Pedro A},
  title = {Development and validation of an ultrafast method of quantification of rivaroxaban in human serum using laser diode thermal desorption coupled to triple quadrupole mass spectrometry},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2024},
  doi = {10.1002/rcm.9855}
}
Start for free →